Have any questions? 706-721-6582 or cts@augusta.edu
- Multilevel Determinants of Treatment Outcomes and Quality of Life in Myeloid Leukemia.
Clinical Trial
Multilevel Determinants of Treatment Outcomes and Quality of Life in Myeloid Leukemia.
This study will examine how patient-reported outcomes, chronic stress, health behaviors, and social determinants of health work together to influence treatment results and health-related quality of life in people with myeloid leukemias. Myeloid leukemias are blood cancers that require long-term, complex treatments. While effective medical care is critical, a patient?s environment, lifestyle, and stress levels can also play a major role in recovery and overall well-being. Chronic stress, when experienced over long periods, can cause lasting strain on the body?s systems, a process known as allostatic load, which may lead to poorer treatment responses. We will use Fitbit devices to track physical activity, sleep quality, and stress patterns in patients and their primary caregivers, and we will measure biological stress levels through allostatic load biomarkers. We will also gather information on social factors such as income, access to healthcare, education, and social support, as these can create barriers to effective treatment. Patients and caregivers will complete surveys to assess quality of life, including physical and emotional symptom burdens.
- Circulatory System
- Allostatic Load
- Biomarkers
- Caregivers
- Chronic Stress
- Health Behaviors
- Health-related Quality Of Life
- Myeloid Leukemia
- Patient-reported Outcomes
- Physical Activity
- Real-world Data.
- Sleep Quality
- Social Determinants Of Health
- Wearable Devices
Eligibility Criteria
- Inclusion Criteria Patients Patients aged 18 years or older who are English-speaking. Diagnosed with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) undergoing treatment that is expected to continue for at least 90 days from the time of enrollment. Willingness and ability to use and maintain a smartwatch (provided) continuously throughout the study duration (6 months). Own a smartphone or compatible device capable of supporting the smartwatch app (iOS or Android). Willingness to give researchers access to their smartwatch data. Control group Serve as a designated support person for the patient, specifically an individual who accompanies the patient to routine clinic appointments. Age 18 years or older who are English-speaking. Willingness and ability to use and maintain a smartwatch (provided) continuously throughout the study duration (6 months). Own a smartphone or compatible device capable of supporting the smartwatch app (iOS or Android). Willingness to give researchers access to their smartwatch data. Exclusion Criteria (Patients and controls) CML patients for whom tyrosine kinase inhibitor (TKI) discontinuation is anticipated within the next 12 months, or those already in treatment-free remission (TFR). Active treatment for a cancer other than myeloid leukemia. Individuals undergoing dialysis. Individuals with serious medical conditions that substantially limit activities of daily living. Cognitive impairment that prevents providing informed consent, completing study questionnaires, or adhering to study procedures. Pregnant individuals, or those planning to become pregnant within the next 6 months.